Paradigm Health today announced SPIRE -- Scalable Platform for Integrated Research & Evidence -- a new model for post-approval and late-stage clinical studies designed to help sponsors generate ...
Paradigm Biopharmaceuticals upsizes placement by 75% Chimeric trial results offer early-stage hope to leukemia patients All ...
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Clinical Trials Arena on MSN
Paradigm Health debuts post-marketing study tool for routine care integration
SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing ...
Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...
COLUMBUS, Ohio and NEW YORK, April 8, 2026 /PRNewswire/ -- New peer-reviewed research demonstrates the feasibility and effectiveness of Paradigm Health's EHR-integrated eSource platform to support ...
Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive ...
The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR ® THV compared to commercially available transcatheter aortic valve ...
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results